20 January 2017 - Two draft science reports on new drugs for type 2 diabetes: second-line therapy : a therapeutic review update are now available for feedback from all interested stakeholders.

CADTH is undertaking a project to assess the clinical and cost-effectiveness of new drugs for the treatment of patients with type 2 diabetes mellitus. These new drugs are in three classes: dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 analogues, and sodium-glucose co-transporter-2 inhibitors. 

As part of this project, recommendations from the CADTH Canadian Drug Expert Committee will be developed.

This project is an update to two large projects on pharmacotherapy for type 2 diabetes mellitus completed by CADTH in the past: an evaluation of second and third-line therapies for type 2 diabetes mellitus originally published in 2010 and an update to this evaluation in 2013.

This project includes several key components:

• A science report on second-line therapy (clinical and economic evaluations)
  
• A science report on third-line therapy (clinical and economic evaluations)
  
• A recommendations report on second-line therapy
  
• A recommendations report on third-line therapy
  

Read draft pharmacoeconomic report